Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits bacterial RNA synthesis
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2004
gptkb:FDA pregnant women severe renal impairment pediatric use |
| gptkbp:brand |
gptkb:Xifaxan
|
| gptkbp:category |
gptkb:unknown
Category C |
| gptkbp:clinical_trial |
Phase III
effective against E. coli effective against C. difficile effective against S. aureus |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to rifaximin |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
14 days for hepatic encephalopathy
2 weeks for IBS-D 3 days for traveler's diarrhea |
| gptkbp:excretion |
primarily in feces
|
| gptkbp:has_ability |
200 mg
|
| https://www.w3.org/2000/01/rdf-schema#label |
rifaximin
|
| gptkbp:indication |
non-invasive bacterial infections
|
| gptkbp:ingredients |
C43 H54 N4 O8 S
|
| gptkbp:interacts_with |
may interact with anticoagulants
may interact with other antibiotics |
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_used_for |
treatment of traveler's diarrhea
treatment of irritable bowel syndrome with diarrhea treatment of hepatic encephalopathy |
| gptkbp:lifespan |
approximately 6 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Salix_Pharmaceuticals
|
| gptkbp:metabolism |
minimal hepatic metabolism
|
| gptkbp:pharmacokinetics |
poorly absorbed in the gastrointestinal tract
|
| gptkbp:provides_information_on |
recommended for IBS-D treatment
recommended for hepatic encephalopathy management not recommended for routine use in non-bacterial infections |
| gptkbp:research_focus |
antibiotic resistance
gut microbiome chronic gastrointestinal disorders |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
dizziness
headache nausea abdominal pain flatulence |
| gptkbp:storage |
store at room temperature
|
| gptkbp:type_of |
80621-81-4
|
| gptkbp:bfsParent |
gptkb:Rifadin
|
| gptkbp:bfsLayer |
5
|